1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

KPTI
Karyopharm Therapeutics Inc.US flagNASDAQ Global Select
9.00
USD
-0.23
- -
203.97MMarket Cap

Total Valuation

Karyopharm Therapeutics Inc. carries a market capitalization of 203.97M, placing it among publicly traded companies globally. Its enterprise value stands at 219.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap203.97M
Enterprise Value219.68M

Share Statistics

Karyopharm Therapeutics Inc. currently has 22.54M shares outstanding.

Shares Outstanding22.54M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 0.53, and the price-to-book ratio stands at -0.04.

PE RatioN/A
PS Ratio0.53
PB Ratio-0.04
P/TBV Ratio-0.30
P/FCF Ratio-1.41
P/OCF Ratio-1.35

Enterprise Valuation

EV / Sales1.45
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Karyopharm Therapeutics Inc. maintains a current ratio of 1.08, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -86.91, indicating conservative leverage, while an interest coverage ratio of -1.77 demonstrates limited ability to service its debt obligations.

Current Ratio1.08
Quick Ratio0.97
Debt / Equity-86.91
Debt / EBITDA-2.75
Interest Coverage-1.77

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-150.48
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.43

Taxes

Income Tax8,000.00
Effective Tax RateN/A

Stock Price Statistics

Karyopharm Therapeutics Inc.'s stock has gained approximately 111.76471% over the past 52 weeks. The 50-day moving average sits at 8.01, while the 200-day moving average is 7.13.

Beta (5Y)N/A
52-Week Price Change111.76471%
50-Day Moving Average8.01
200-Day Moving Average7.13
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Karyopharm Therapeutics Inc. generated 151.12M in revenue and converted that into -194.97M in net income, yielding earnings per share of -13.02. EBITDA reached -83.98M, while operating income came in at -84.21M.

Revenue151.12M
Gross Profit145.13M
Operating Income-84.21M
Pretax Income-194.96M
Net Income-194.97M
EBITDA-83.98M
EBIT-84.21M
Earnings Per Share (EPS)-13.02

Balance Sheet

Karyopharm Therapeutics Inc. holds 90.85M in cash and equivalents against 230.87M in total debt, resulting in a net debt position of 133.54M. Total book value stands at -1.78B, with working capital of 9.03M providing operational flexibility.

Cash & Cash Equivalents90.85M
Total Debt230.87M
Net Debt133.54M
Equity (Book Value)-1.78B
Book Value Per Share-124.59
Working Capital9.03M

Cash Flow

Karyopharm Therapeutics Inc. produced -59.11M in operating cash flow over the past twelve months.

Operating Cash Flow-59.11M
Capital ExpendituresN/A
Free Cash Flow-59.11M
FCF Per Share-4.13

Margins

Karyopharm Therapeutics Inc. operates with a gross margin of 96.03, reflecting its pricing power and cost economics. The operating margin of -55.73 and net profit margin of -129.02 provide insight into operational efficiency.

Gross Margin96.03
Operating Margin-55.73
Pretax Margin-129.01
Profit Margin-129.02
EBITDA Margin-55.57

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-100.24
FCF Yield-70.86

Stock Splits

Karyopharm Therapeutics Inc.'s most recent stock split took place on February 26, 2025 with a 15:1 split ratio.

Last Split Date2/26/2025
Split Ratio15:1

Scores

Karyopharm Therapeutics Inc. posts an Altman Z-Score of -19.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-19.74